Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Viramidine (Ribapharm).

Dale Barnard1

  • 1Institute for Antiviral Research, Utah State University, 5600 Old Main Hill Logan, UT 84322-5600, USA. honery@cc.usu.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|December 13, 2002
PubMed
Summary

Viramidine, a ribavirin analog, is being developed as a broad-spectrum antiviral. Clinical trials are underway for its potential use in treating viral infections, including chronic hepatitis C virus (HCV) infection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Endoplasmic Reticulum α-Glucosidase I with a Single-Dose Iminosugar Treatment Protects against Lethal Influenza and Dengue Virus Infections.

Journal of medicinal chemistry·2020
Same author

Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant.

Methods in molecular biology (Clifton, N.J.)·2016
Same author

Protease inhibitors targeting coronavirus and filovirus entry.

Antiviral research·2015
Same author

Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.

Journal of virology·2014
Same author

Commentary on Immune System Associated Diseases Caused by Viruses: The Role of EBV.

Frontiers in microbiology·2011

Area of Science:

  • Antiviral drug development
  • Hepatology
  • Clinical pharmacology

Background:

  • Viramidine is a novel broad-spectrum antiviral agent.
  • It is an analog of ribavirin, developed by Ribapharm.
  • Viramidine is under investigation for treating various viral infections.

Purpose of the Study:

  • To evaluate the clinical development of viramidine.
  • To assess viramidine in combination therapy for chronic hepatitis C virus (HCV) infection.
  • To determine the safety and efficacy of viramidine in clinical trials.

Main Methods:

  • Phase I clinical trials initiated in Europe (September 2000) and the US (March 2002).
  • US Investigational New Drug (IND) application filed for combination therapy with interferon-alpha for chronic HCV (December 2001).
  • Phase II trials planned for chronic HCV treatment (initiated by end of 2002).

Main Results:

  • Viramidine has advanced to Phase I and Phase II clinical trials.
  • The drug is being studied as a potential treatment for chronic hepatitis C virus infection.
  • Combination therapy with interferon-alpha is being investigated.

Conclusions:

  • Viramidine shows promise as a broad-spectrum antiviral agent.
  • Clinical development is progressing for viramidine, particularly for chronic HCV.
  • Further trials are needed to establish its therapeutic role.

Related Experiment Videos